Lewis Water Restoration Explains What Property Owners Should Check After Recent Heavy Rain and Northeast Storm Conditions

Lewis Water Restoration is encouraging Paterson property owners to check for hidden moisture following recent heavy rain and strong winds in North Jersey. Founded in 2012, the company highlights basements, walls, ceilings, flooring, plumbing, and other vulnerable areas where water intrusion may not be immediately visible, along with warning signs that can indicate developing water or mold problems.

Paterson, NJ - October 7, 2026 - Following a stretch of significant September weather in North Jersey, Lewis Water Restoration is encouraging Paterson property owners to check homes and businesses for signs of water intrusion and lingering moisture. The National Weather Service issued flood-related alerts for eastern Passaic County during heavy rainfall in September, and Paterson was also under a Wind Advisory during the late-September nor’easter, making early October a timely opportunity to examine areas where storm-related moisture may not be immediately visible.

Founded in 2012 and owned by Jayden Cox, Lewis Water Restoration provides property restoration services in Paterson and surrounding North Jersey communities. The company specializes in Water Damage Restoration, Fire Damage Restoration, Mold Remediation, and Burst Pipe Repair, helping property owners respond to damage caused by water, moisture, plumbing failures, and other property emergencies.

One of the first places property owners should check after periods of heavy rain is the basement or lowest level of the building. Water can enter through vulnerable foundation areas, basement windows, exterior openings, drainage problems, or other pathways. Even when standing water is not present, damp walls, staining, peeling finishes, unusual odors, or changes in flooring can indicate that moisture entered the structure.

“Water damage is not always as obvious as a flooded room,” said Jayden Cox, owner of Lewis Water Restoration. “After significant rainfall, property owners should pay attention to smaller changes such as staining, damp materials, musty odors, or flooring that begins to look or feel different. Finding the source of moisture early can help determine what needs to be addressed.”

The recent weather provides a relevant reminder for North Jersey. On September 13, the National Weather Service reported flash flooding in eastern Passaic County after heavy rainfall, with radar and automated gauges indicating between one and 2.5 inches had already fallen in the warned area at one point. Later in the month, another storm brought rain and strong winds to the Paterson area, with the National Weather Service forecasting wind gusts as high as 40 mph on September 27.

Following substantial rainfall, professional Water Damage Restoration may involve more than removing visible water. The affected materials and the path the water traveled also need to be considered. Drywall, insulation, flooring, subflooring, cabinetry, and other porous materials can retain moisture even after exposed surfaces appear dry.

Ceilings and upper walls should also be checked. Roof or flashing problems can allow rainwater to enter higher portions of a building before moisture eventually becomes visible indoors. Discoloration, bubbling paint, softened drywall, or new stains can warrant further investigation.

Windows and exterior doors represent additional areas to examine. Property owners may notice staining around frames, damp trim, deteriorated sealant, or moisture along nearby flooring following wind-driven rain.

Another concern is moisture that remains trapped long enough to create conditions favorable to microbial growth. Mold Remediation may become necessary when mold growth is identified and the underlying moisture source has been addressed. Simply cleaning a visible surface without determining why it became damp can leave the original problem unresolved.

Musty odors can be an important warning sign, particularly in basements, closets, wall cavities, utility areas, and rooms that receive limited airflow. A persistent odor does not by itself identify the source, but it can indicate that an area warrants closer evaluation.

Property owners should also distinguish storm-related water entry from plumbing problems. A damp wall, ceiling stain, or wet floor can sometimes result from a leaking supply line, drain, appliance connection, or another plumbing component rather than exterior rainfall.

This becomes increasingly relevant as New Jersey moves toward colder weather. Plumbing systems located in vulnerable or inadequately protected areas can face additional challenges as temperatures decline. Professional Burst Pipe Repair may be required when a pipe fails and releases water into walls, ceilings, floors, basements, or other areas of a property.

Knowing the location of the property's main water shutoff can be useful before an emergency occurs. If a significant plumbing leak develops, stopping the water supply when it is safe and practical to do so can help limit continued water release while professional assistance is arranged.

Businesses and commercial property owners should perform similar checks following severe weather. Storage areas, mechanical rooms, basements, roof penetrations, ceiling tiles, exterior walls, and areas around doors and windows can reveal evidence of water entry.

Documentation can also be valuable. Photographing visible damage and noting when moisture or staining first appeared can help property owners maintain a clearer record of the incident and subsequent restoration work.

Although water-related issues are a major focus following storms, restoration planning can involve other types of property damage as well. Fire Damage Restoration can require assessment of fire-affected materials along with smoke, soot, odors, and water introduced during firefighting efforts. Each type of loss requires evaluation based on the materials and areas actually affected.

Lewis Water Restoration emphasizes that property owners should avoid assuming a building is completely dry simply because visible water has disappeared. Moisture can migrate beneath flooring, behind walls, into insulation, and through other concealed building materials.

At the same time, evidence of moisture does not automatically mean extensive restoration is required. The appropriate response depends on where the water originated, how much entered the property, how long materials remained wet, and which components were affected.

For Paterson homeowners and businesses, early October provides a useful opportunity to check properties following September's periods of heavy rainfall and strong winds while also preparing for colder weather ahead.

Lewis Water Restoration continues to help residential and commercial property owners throughout Paterson and surrounding North Jersey communities evaluate water-related property damage and determine appropriate drying, restoration, and remediation options.

Property owners who discover unexplained moisture, staining, water damage, mold concerns, or plumbing-related damage can contact Lewis Water Restoration in Paterson, New Jersey for a professional property evaluation.

About Lewis Water Restoration

Lewis Water Restoration is a property restoration company based in Paterson, New Jersey. Founded in 2012 and owned by Jayden Cox, the company specializes in water damage restoration, fire damage restoration, mold remediation, and burst pipe repair for residential and commercial properties in Paterson and surrounding North Jersey communities.

Media Contact
Company Name: Lewis Water Restoration
Contact Person: Jayden Cox
Email:Send Email
Phone: 973-899-9030
Address:277 Main St Ste 1
City: Paterson
State: NJ
Country: United States
Website: https://www.lewiswaterrestoration.com/

Reverse Mortgage Requirements in Canada: New Guide Sets Out Who Qualifies

A new guide lists the reverse mortgage requirements in Canada in full, and explains why the two things most homeowners worry about, income and credit, are not the deciding factors.

HAMILTON, Ontario - October 7, 2026 - The reverse mortgage requirements in Canada are shorter than most homeowners expect, according to a new guide published by an independent Ontario mortgage brokerage for homeowners aged 55 and over.

The requirements for a reverse mortgage come down to three things. Every owner on title must be 55 or older. The home must be the borrower's primary residence. And the property's type, value and location must meet the lender's rules.

What is absent from that list is the part that stops most people from asking. There is no income qualification of the kind a bank applies, and no stress test. Approval rests mainly on age, the home's value and where it is. Credit is reviewed, but it does not work the way it does on a conventional mortgage application.

"People talk themselves out of this before they ask. They assume their pension is too small or their credit is too marked up. Neither is the test," said Richard Hopkins, Mortgage Broker, licence M16000896.

The guide answers the questions homeowners raise most often about reverse mortgage eligibility:

Do condominiums qualify? Yes. So do detached homes, semis and townhouses. Lenders assess the individual unit's value, the building and the location.

What if there is still a mortgage on the home? An existing mortgage or home equity line of credit does not disqualify anyone. It is paid off and closed from the proceeds, and that is the single most common use of a reverse mortgage in Canada.

Does both spouses' age matter? Every owner on title must meet the minimum age, so the younger spouse usually sets the amount available. One lender's rules differ on whose name must be on title, which can change the outcome on the right file, and the guide explains when that is worth exploring.

How much does meeting the requirements unlock? Homeowners typically access a fifth to over half of the home's value, with the share rising by age and the market's top tier reserved for older borrowers.

Can an application be declined? Yes. The guide is direct about the property types and situations that lenders turn down, so homeowners can find that out before an appraisal is paid for.

Ontario requires every reverse mortgage borrower to receive independent legal advice from their own lawyer before closing, which is a requirement of the transaction rather than of qualifying.

The guide is written by Richard Hopkins, a Mortgage Broker (licence M16000896) with Dominion Lending Centres Homestead Financial, an independent Ontario brokerage licensed by the Financial Services Regulatory Authority of Ontario (brokerage licence #11711). It is free to read at:

https://reversemortgagebroker.ca/reverse-mortgage-requirements/?utm_source=abnewswire&utm_medium=press_release&utm_campaign=pr07-requirements

Homeowners can check what they qualify for with a free estimate, with no credit check and no sales pressure.

About Dominion Lending Centres Homestead Financial

Dominion Lending Centres Homestead Financial is an independent mortgage brokerage in Hamilton, Ontario, licensed by the Financial Services Regulatory Authority of Ontario (brokerage licence #11711) and in business since 1999. More than 1,200 Ontario families have arranged a mortgage through the brokerage. Independently Owned and Operated. Richard Hopkins, Mortgage Broker (licence M16000896), leads its reverse mortgage practice.

Media Contact
Company Name: Homestead Financial
Contact Person: Richard Hopkins
Email:Send Email
Phone: 905-690-6068
Address:26 Glaceport Ave
City: Dundas
State: Ontario
Country: Canada
Website: https://reversemortgagebroker.ca/reverse-mortgage-requirements/?utm_source=abnewswire&utm_medium=press_release&utm_campaign=pr07-requirements

Diabetic Macular Edema Market is Projected to Grow by 2036 Owing to Rising Diabetes Burden and Advancements in Long-Acting Retinal Therapies | DelveInsight

The market dynamics for Diabetic Macular Edema are witnessing steady growth driven by the increasing prevalence of diabetes, growing disease burden, improvements in retinal screening and diagnosis, continued dominance of anti-VEGF therapies, and increasing adoption of long-acting and sustained-delivery treatments. The treatment landscape is also expanding beyond conventional VEGF inhibition, with emerging therapies targeting novel biological pathways and alternative routes of administration.

(Albany, New York) – October 07, 2026 - The market dynamics for Diabetic Macular Edema (DME) are witnessing steady growth driven by the increasing prevalence of diabetes, growing disease burden, improvements in retinal screening and diagnosis, continued dominance of anti-VEGF therapies, and increasing adoption of long-acting and sustained-delivery treatments. The treatment landscape is also expanding beyond conventional VEGF inhibition, with emerging therapies targeting novel biological pathways and alternative routes of administration. The development of therapies such as OCS-01, RG6351, and Restoret (MK-3000) is expected to further reshape the DME market by addressing treatment durability, injection burden, and inadequate response to existing therapies.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Diabetic Macular Edema (DME) Market Insights, Epidemiology, and Market Forecast – 2036.” The report provides an in-depth assessment of the DME market, including historical and forecasted epidemiology, treatment practices, emerging therapies, market dynamics, competitive landscape, and growth opportunities across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Diabetic Macular Edema Market Report

• The 7MM Diabetic Macular Edema market was approximately USD 4,000 million in 2025 and is projected to grow at a 3.5% CAGR during 2026–2036.

• The United States accounted for approximately USD 2,200 million in DME market size in 2025, representing the largest share among the 7MM.

• The United States represented approximately 60% of the total 7MM DME market in 2025, followed by Germany and Japan.

• The total diagnosed prevalent DME population across the 7MM was approximately 900,000 cases in 2025.

• In the United States, DME prevalence was higher among males, at approximately 300,000 cases, compared with around 210,000 cases among females in 2025.

• The 45–64 years age group accounted for approximately 224,000 DME cases in the United States in 2025, followed by individuals aged ≥75 years with approximately 220,000 cases.

• Anti-VEGF therapies remain the backbone of DME treatment, with EYLEA, LUCENTIS, BEOVU, and VABYSMO among the major therapies used in clinical practice.

• The treatment landscape is increasingly moving toward long-acting therapies, sustained drug delivery, biosimilars, and non-VEGF mechanisms to reduce injection frequency and improve treatment outcomes.

• Key emerging therapies include OCS-01, RG6351, and Restoret (MK-3000).

• Major companies active in the DME market include Regeneron Pharmaceuticals/Bayer, Genentech, Bayer, Roche, Novartis, Sandoz, Oculis, and Merck, among others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market

Key Factors Driving the Diabetic Macular Edema Market

Rising Diabetes Burden and DME Patient Population

The increasing prevalence of Diabetes Mellitus is one of the fundamental factors supporting the expansion of the DME market. DME develops as a complication of diabetic retinopathy, with chronic hyperglycemia damaging retinal blood vessels and increasing vascular permeability. Poor glycemic control, longer duration of diabetes, hypertension, obesity, and population aging further contribute to the risk of developing DME. As the global diabetic population continues to expand, the addressable population requiring retinal screening, monitoring, and treatment is also increasing.

Increasing Adoption of Anti-VEGF Therapies

Anti-VEGF therapies have fundamentally changed DME management by reducing abnormal vascular permeability and improving retinal thickness and visual outcomes. Aflibercept, ranibizumab, brolucizumab, and faricimab form an important part of the current treatment landscape. Their established efficacy and widespread clinical adoption continue to support the commercial value of the DME market.

Shift Toward Long-Acting and Sustained-Delivery Treatments

The high frequency of intravitreal injections represents a significant burden for DME patients and healthcare providers. Consequently, the development of long-acting implants and sustained-delivery technologies is becoming increasingly important. SUSVIMO, a ranibizumab implant, represents an important advancement because it can provide sustained intraocular drug delivery and reduce the frequency of conventional injections.

Expansion of Biosimilars and Cost-Effective Treatment Options

The emergence of biosimilar therapies is expected to increase competition and potentially improve affordability and patient access. OPUVIZ (aflibercept-yszy) and ENZEEVU (aflibercept-abzv) are contributing to the expanding biosimilar landscape in retinal diseases, including DME. Greater availability of lower-cost alternatives could influence prescribing patterns and market access, particularly in cost-sensitive healthcare systems.

Emergence of Non-VEGF and Non-Invasive Therapies

The DME pipeline is increasingly moving toward mechanisms beyond conventional VEGF inhibition. Novel approaches include WNT pathway modulation, Tie-2 pathway activation, topical corticosteroid delivery, and gene-based approaches. Such therapies could be particularly valuable for patients who respond inadequately to anti-VEGF therapy or require more durable disease control.

Diabetic Macular Edema Competitive Landscape

The DME competitive landscape is highly dynamic, with established pharmaceutical companies competing across anti-VEGF therapies, corticosteroids, sustained-delivery systems, biosimilars, and emerging targeted treatments. Major companies identified by DelveInsight include Regeneron Pharmaceuticals/Bayer, Genentech, Bayer, Roche, Novartis, Sandoz, Oculis, and Merck.

Among marketed therapies, EYLEA (aflibercept) remains an important anti-VEGF therapy. It acts as a VEGF trap by binding VEGF-A, VEGF-B, and placental growth factor. EYLEA received US FDA approval for DME in 2014. LUCENTIS (ranibizumab), marketed by Genentech in the United States, is another established anti-VEGF treatment approved for DME.

VABYSMO (faricimab) introduced dual-pathway inhibition by simultaneously targeting VEGF-A and Ang-2, providing an additional mechanism for improving vascular stability and treatment durability. Meanwhile, BEOVU (brolucizumab) provides another anti-VEGF option with extended dosing potential.

The competitive environment is further intensifying with biosimilars and emerging long-acting formulations, which could influence pricing, accessibility, patient adherence, and market share over the forecast period.

Discover more about therapies set to impact the Diabetic Macular Edema market @Diabetic Macular Edema Treatment Landscape

Recent Developments in the Diabetic Macular Edema Market

• April 2026: Regeneron Pharmaceuticals announced that the US FDA approved an extension of EYLEA dosing intervals to up to every 20 weeks for patients with wet age-related macular degeneration and DME following one year of successful response.

• February 2026: Sandoz announced US FDA approval of an expanded label for ENZEEVU, adding retinal indications including diabetic retinopathy and DME, alongside its previously approved indication for neovascular age-related macular degeneration.

• February 2025: Roche received US FDA approval for ranibizumab implant (SUSVIMO) for DME, providing a long-acting ocular treatment option designed to reduce treatment frequency compared with conventional monthly injections.

• September 2025: Oculis presented expanded analyses from the Phase III DIAMOND program evaluating OCS-01 eye drops in DME at the EURETINA Congress.

• April 2025: Oculis announced completion of enrollment in the DIAMOND-1 and DIAMOND-2 Phase III trials of OCS-01 in DME, with topline data anticipated in the second quarter of 2026 and a planned US FDA NDA submission in the fourth quarter of 2026.

• May 2024: Merck announced its acquisition of EyeBio, obtaining rights to Restoret (MK-3000), an investigational WNT pathway agonist being developed for DME and neovascular age-related macular degeneration.

What is Diabetic Macular Edema?

Diabetic Macular Edema (DME) is a vision-threatening complication of diabetic retinopathy characterized by the accumulation of fluid within the macula due to leakage from damaged retinal blood vessels. The resulting retinal thickening can impair central vision and, if inadequately managed, lead to significant visual impairment. DME is an important cause of vision loss among working-age adults.

Chronic hyperglycemia damages the blood-retinal barrier and increases vascular permeability, promoting fluid accumulation in the macular region. The increasing prevalence of diabetes, together with aging populations, sedentary lifestyles, and obesity, is contributing to the broader disease burden.

Diagnosis generally involves clinical retinal examination and imaging. Optical coherence tomography (OCT) is a key diagnostic tool for identifying retinal thickening and fluid accumulation, while fluorescein angiography may be used to assess vascular leakage and retinal perfusion.

DME can be classified into center-involved DME (CI-DME), where the fovea is affected, and non-center-involved DME (NCI-DME), where the central macula is spared.

Diabetic Macular Edema Epidemiology Segmentation

DelveInsight's epidemiological assessment of DME includes:

• Total prevalent cases

• Total diagnosed prevalent cases

• Gender-specific diagnosed prevalent cases

• Age-specific diagnosed prevalent cases

• Subgroup-specific diagnosed prevalent cases

• Total treated cases

According to DelveInsight estimates, the total diagnosed prevalent DME population across the 7MM was approximately 900,000 cases in 2025.

In the United States, approximately 300,000 DME cases were observed among males compared with approximately 210,000 among females in 2025. The 45–64 years age group represented the largest age category, with approximately 224,000 cases, followed by individuals aged ≥75 years, with approximately 220,000 cases.

Among the EU4 and the UK, Germany recorded the highest number of DME cases in 2025, followed by France, while Spain recorded the lowest number. Japan accounted for approximately 10% of the total diagnosed prevalent DME population across the 7MM in 2025.

Current Diabetic Macular Edema Treatment Landscape

The current DME treatment landscape is primarily dominated by intravitreal anti-VEGF therapies, which are considered first-line treatments because of their ability to reduce vascular leakage, retinal thickness, and vision loss. Key therapies include EYLEA, LUCENTIS, BEOVU, and VABYSMO.

Aflibercept (EYLEA) inhibits VEGF-A, VEGF-B, and placental growth factor and has been an important component of DME treatment since its FDA approval for the indication in 2014. Ranibizumab (LUCENTIS) is another established anti-VEGF therapy approved for DME in the United States.

Faricimab (VABYSMO) provides dual inhibition of VEGF-A and Ang-2 and has expanded the treatment paradigm toward improved vascular stability and potentially longer dosing intervals.

For patients with inadequate response to anti-VEGF therapy, corticosteroids can be used as second-line treatment. Dexamethasone and fluocinolone implants reduce inflammation and vascular leakage but may be associated with adverse effects including increased intraocular pressure and cataract formation.

Laser photocoagulation continues to have a role in selected patients, while advances in laser technologies are intended to improve treatment precision and reduce collateral retinal damage.

Unmet Needs in the Diabetic Macular Edema Market

Despite substantial advances, significant unmet needs remain in DME management. One of the most important challenges is the limited durability of existing anti-VEGF therapies, which can require repeated intravitreal injections over prolonged periods. This creates treatment burden for patients and healthcare providers and can contribute to adherence challenges.

A further unmet need is the management of anti-VEGF non-responders. A proportion of patients does not achieve adequate disease control with existing therapies, highlighting the need for alternative mechanisms of action. Long-acting and sustained-delivery approaches are therefore receiving increasing attention.

Other challenges include treatment-related adverse effects, high long-term treatment costs, access barriers, delayed diagnosis in asymptomatic patients, limited biomarker-driven treatment selection, recurrence, and the need for continuous monitoring.

The emergence of non-invasive and novel mechanism-based treatments could address several of these limitations and create new opportunities within the DME therapeutic market.

Scope of the Diabetic Macular Edema Market Report

The report covers the 2022–2036 study period, with 2022–2025 representing the historical period, 2026–2036 the forecast period, and 2026 the base year. The geographic scope includes the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

The report provides comprehensive analysis of:

• DME epidemiology and patient burden

• Historical and forecasted market size

• Current treatment practices and treatment algorithms

• Marketed and emerging therapies

• Drug uptake and patient-share analysis

• Competitive landscape

• Clinical trial developments

• Market access and reimbursement

• Pricing and analogue assessment

• Key opinion leader insights

• SWOT analysis

• Conjoint analysis

• Market drivers and barriers

• Unmet medical needs

• Future market opportunities

To know more about Diabetic Macular Edema companies, clinical trials, and therapeutic assessment, request a sample @Diabetic Macular Edema Market Report Sample

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Diabetic Macular Edema Market Overview at a Glance

7. Diabetic Macular Edema Disease Background and Overview

8. Diabetic Macular Edema Epidemiology and Patient Population

9. Diabetic Macular Edema Current Treatment Practices

10. Diabetic Macular Edema Marketed Therapies

11. Diabetic Macular Edema Emerging Therapies

12. Diabetic Macular Edema Drug Analysis and Competitive Landscape

13. Diabetic Macular Edema Market Outlook

14. Diabetic Macular Edema Market Size and Forecast

15. Diabetic Macular Edema Drug Uptake Analysis

16. Diabetic Macular Edema Market Access and Reimbursement

17. Diabetic Macular Edema Pricing and Analogue Assessment

18. Diabetic Macular Edema Unmet Needs

19. KOL Views and Expert Insights

20. SWOT and Conjoint Analysis

21. Market Drivers and Barriers

22. Appendix

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Dravet Syndrome Market is Projected to Grow by 2036 Owing to Rising Diagnosis and Advancements in Gene-Targeted Therapies | DelveInsight

The market dynamics for Dravet syndrome are witnessing steady growth, driven by increasing disease awareness, improvements in genetic testing and diagnosis, growing adoption of targeted anti-seizure therapies, and continued investment in precision and disease-modifying approaches. The therapeutic landscape is gradually shifting beyond conventional symptomatic seizure management toward treatments targeting the underlying SCN1A dysfunction.

(Albany, New York) – October 07, 2026 - The market dynamics for Dravet syndrome are witnessing steady growth, driven by increasing disease awareness, improvements in genetic testing and diagnosis, growing adoption of targeted anti-seizure therapies, and continued investment in precision and disease-modifying approaches. The therapeutic landscape is gradually shifting beyond conventional symptomatic seizure management toward treatments targeting the underlying SCN1A dysfunction. Additionally, the development of emerging therapies such as zorevunersen (STK-001), bexicaserin (LP352), clemizole hydrochloride (EPX-100), and ETX101 is expected to further transform the Dravet syndrome treatment landscape during the forecast period.

DelveInsight, a leading market research firm, announces the release of its latest report, “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast – 2036.” The report provides an in-depth analysis of Dravet syndrome, including historical and forecasted epidemiology, existing treatment practices, emerging therapies, market trends, competitive dynamics, and growth opportunities across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Dravet Syndrome Market Report

• The Dravet syndrome market is expected to expand at a healthy growth rate during 2026–2036, supported by the introduction of new therapies and an increasing diagnosed patient population. The public report page currently masks the numerical 2025 and 2036 market values and CAGR as XXX/XX%, so no numerical market estimate has been stated here.

• The total diagnosed prevalent population of Dravet syndrome across the 7MM was approximately 25,600 cases in 2025.

• The United States accounted for approximately 50% of diagnosed prevalent Dravet syndrome cases in the 7MM in 2025, representing the largest patient share among the covered markets.

• The prevalence of Dravet syndrome has been estimated at approximately 1 in 20,000 to 1 in 40,000 individuals.

• SCN1A mutations represent a major genetic feature of Dravet syndrome, with the report indicating that approximately 80–90% of cases are associated with mutations in the SCN1A gene.

• Existing management includes combinations of fenfluramine, cannabidiol, stiripentol, valproate, and clobazam, together with trigger management, rescue medication, and long-term developmental and behavioral support.

• Key marketed therapies include EPIDIOLEX/EPIDYOLEX (cannabidiol), FINTEPLA (fenfluramine), and DIACOMIT (stiripentol).

• Prominent emerging therapies include zorevunersen (STK-001), bexicaserin (LP352), clemizole hydrochloride (EPX-100), and ETX101, reflecting growing development activity across antisense oligonucleotides, targeted small molecules, and gene therapy.

• Major companies active in the Dravet syndrome treatment landscape include Stoke Therapeutics, Biogen, Longboard Pharmaceuticals, Harmony Biosciences, Encoded Therapeutics, Jazz Pharmaceuticals, UCB, Zogenix, and BIOCODEX, among others.

Keen to know more about the market? Request our sample page at:https://www.delveinsight.com/sample-request/dravet-syndrome-market

Key Factors Driving the Dravet Syndrome Market

The growing diagnosed patient population and improvements in disease recognition represent important factors supporting market development. Dravet syndrome is a rare developmental and epileptic encephalopathy that generally begins during infancy. Greater clinical awareness and increasing access to genetic testing are facilitating more accurate identification of patients, particularly those carrying disease-associated SCN1A mutations.

Another major growth factor is the transition toward precision and mechanism-based therapies. Existing treatments primarily focus on controlling seizures, whereas emerging approaches increasingly aim to address the molecular basis of the disease. Antisense oligonucleotides and gene-regulation therapies targeting SCN1A dysfunction could substantially alter the future treatment paradigm if their clinical development is successful.

The high unmet medical need is also encouraging continued pharmaceutical investment. Despite multiple anti-seizure therapies, many patients remain inadequately controlled, while cognitive, developmental, behavioral, and motor manifestations contribute significantly to long-term disease burden. Safety issues, treatment burden, heterogeneous response, and the absence of curative therapies continue to create opportunities for differentiated treatments.

Dravet Syndrome Competitive Landscape

The Dravet syndrome competitive landscape is evolving from established anti-seizure medications toward precision genetic therapies and targeted neuromodulators. Companies highlighted in DelveInsight's report include Stoke Therapeutics, Biogen, Longboard Pharmaceuticals, Harmony Biosciences, Encoded Therapeutics, Jazz Pharmaceuticals, UCB, Zogenix, and BIOCODEX, among others.

Among the prominent pipeline candidates, zorevunersen (STK-001) from Stoke Therapeutics and Biogen is an investigational antisense oligonucleotide designed to increase NaV1.1 protein expression by leveraging the functional copy of SCN1A. The report lists the candidate in Phase III development.

Bexicaserin (LP352) is listed as a Phase III oral small molecule targeting the serotonin 5-HT2C pathway, while clemizole hydrochloride (EPX-100) is another Phase III oral candidate acting through central serotonin receptors.

ETX101, being developed by Encoded Therapeutics, represents a different therapeutic strategy. It is an AAV9-based, cell-selective gene-regulation therapy designed as a potential one-time disease-modifying treatment for patients with SCN1A-positive Dravet syndrome. The DelveInsight report lists ETX101 in Phase I/II development.

Discover more about therapies set to impact the Dravet Syndrome market @Dravet Syndrome Treatment Landscape

Recent Developments in the Dravet Syndrome Market

• In April 2026, Jazz Pharmaceuticals presented research concerning EPIDIOLEX (cannabidiol) Oral Solution in Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting.

• In March 2026, Stoke Therapeutics and Biogen reported clinical findings concerning zorevunersen from Phase I/IIa and extension-study evaluations, providing early evidence supporting its potential as a disease-modifying approach for Dravet syndrome.

• In March 2026, Encoded Therapeutics announced completion of an RMAT meeting with the US FDA and alignment regarding the pivotal study design intended to support a future BLA submission for ETX101.

• In January 2026, the development program for zorevunersen included the Phase III EMPEROR study, with the report noting plans for a mid-2027 data readout to support a rolling NDA submission.

• In January 2026, the US FDA granted Breakthrough Therapy Designation to ETX101 for SCN1A-positive Dravet syndrome.

• In December 2025, Encoded Therapeutics announced positive interim findings from the POLARIS clinical development program evaluating ETX101 in children with SCN1A-positive Dravet syndrome.

What is Dravet Syndrome?

Dravet syndrome, historically referred to as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare, lifelong developmental and epileptic encephalopathy that generally begins during infancy. Patients experience prolonged and frequently treatment-resistant seizures accompanied by developmental, cognitive, behavioral, motor, and speech-related complications.

Seizures typically begin during the first year of life and may initially be triggered by fever. A substantial proportion of Dravet syndrome cases are associated with mutations in the SCN1A gene, which encodes a voltage-gated sodium-channel protein involved in neuronal signaling. Because clinical manifestations evolve over time and can overlap with other childhood epilepsy syndromes, diagnosis can be challenging. Genetic testing for SCN1A mutations has therefore become an important component of diagnostic confirmation.

The disease requires lifelong multidisciplinary management, encompassing seizure control, emergency seizure management, developmental support, behavioral care, and safety interventions.

Dravet Syndrome Epidemiology Segmentation

DelveInsight's epidemiological model evaluates the Dravet syndrome patient population across the 7MM using the following segments:

• Total Dravet Syndrome Diagnosed Prevalent Cases

• Mutation-specific Diagnosed Prevalent Cases

• Age-specific Diagnosed Prevalent Cases

• Gender-specific Diagnosed Prevalent Cases

The total diagnosed prevalent population across the 7MM reached approximately 25,600 cases in 2025, with the United States accounting for approximately half of diagnosed cases. The epidemiological assessment also indicates that SCN1A mutations are associated with approximately 80–90% of Dravet syndrome cases, highlighting the importance of mutation-specific diagnosis and therapeutic development.

Current Dravet Syndrome Treatment Landscape

Treatment currently focuses primarily on reducing seizure frequency and severity, preventing prolonged seizures and status epilepticus, and managing developmental and behavioral complications. Combination anti-seizure therapy commonly involves agents such as valproate, clobazam, stiripentol, cannabidiol, and fenfluramine. Sodium-channel-blocking anti-seizure medications are generally avoided because they may worsen seizures in Dravet syndrome.

Among disease-specific marketed treatments, EPIDIOLEX/EPIDYOLEX (cannabidiol) is an oral therapy used for seizures associated with Dravet syndrome. FINTEPLA (fenfluramine) is another established treatment and is marketed in the United States, Europe, and Japan. DIACOMIT (stiripentol) is also an important component of the existing therapeutic landscape.

Non-pharmacological approaches, including the ketogenic diet, may be considered for selected patients. Rescue medication is important for prolonged seizures, while multidisciplinary care addresses developmental, cognitive, behavioral, and safety needs.

The emerging pipeline represents a potentially important transition from symptomatic treatment toward disease-modifying intervention, particularly through therapies designed to increase functional NaV1.1 expression or regulate SCN1A activity.

Unmet Needs in the Dravet Syndrome Market

Despite improvements in seizure management, substantial unmet needs remain. There is currently a need for therapies capable of addressing the underlying genetic cause of disease rather than primarily controlling seizures. Many patients continue to experience refractory seizures despite multidrug treatment, while developmental and behavioral comorbidities remain a major contributor to overall disease burden.

Additional challenges include treatment-related safety concerns, drug interactions, heterogeneous treatment response, chronic treatment burden, and limited therapeutic choices due to the need to avoid certain sodium-channel-blocking medications. Consequently, therapies capable of providing durable seizure control together with improvements in cognitive, developmental, behavioral, and motor outcomes could address a substantial unmet need.

Scope of the Dravet Syndrome Market Report

The report covers a study period from 2022 to 2036, with 2022–2025 as the historical period, 2026–2036 as the forecast period, and 2026 as the base year. Geographic coverage includes the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

The report provides comprehensive coverage of:

• Dravet syndrome epidemiology and patient-burden forecasts

• Historical and forecasted market trends

• Current treatment practices and treatment algorithms

• Marketed and emerging therapy assessment

• Drug uptake and market-share analysis

• Competitive and clinical-development landscape

• Market access and reimbursement

• Pricing and analogue assessment

• SWOT and conjoint analysis

• Key opinion leader insights

• Unmet needs and future market opportunities

To know more about Dravet Syndrome companies, clinical trials, and therapeutic assessment, request a sample @Dravet Syndrome Market Report Sample

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Dravet Syndrome Market Overview at a Glance

7. Dravet Syndrome Disease Background and Overview

8. Dravet Syndrome Epidemiology and Patient Population

9. Dravet Syndrome Current Treatment Practices

10. Dravet Syndrome Marketed Therapies

11. Dravet Syndrome Emerging Therapies

12. Dravet Syndrome Drug Analysis and Competitive Landscape

13. Dravet Syndrome Market Outlook

14. Dravet Syndrome Market Size and Forecast

15. Dravet Syndrome Drug Uptake Analysis

16. Dravet Syndrome Market Access and Reimbursement

17. Dravet Syndrome Pricing and Analogue Assessment

18. Dravet Syndrome Unmet Needs

19. KOL Views and Expert Insights

20. SWOT and Conjoint Analysis

21. Market Drivers and Barriers

22. Appendix

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Mole Launches AI SEO & GEO Agent to Help Teams Rank on Google and ChatGPT

AI SEO Agent Mole Capabilities

Mole, an AI SEO & GEO Agent, has launched to help startups, agencies, and growth teams automate SEO research, page work, indexing, and review — without handing strategy to a bot. Mole assigns each client an isolated agent that turns company and customer context into SEO work a human reviews and approves, keeping the strategy and client relationship with the team.

SINGAPORE, October 07, 2026 — Mole, an AI SEO & GEO Agent, has launched to automate and expedite how teams execute their own search strategy across Google and AI engines like ChatGPT, Perplexity, and Claude.

Launched to its first cohort of startups and businesses on 21 September 2026, Mole assigns each client an isolated AI agent that starts from the company's own product and customer details, then turns that context into SEO work the team can review and build on. Rather than handing SEO to a "black box" bot, or reporting data that still leaves a human team to carry the work, Mole keeps the strategy, judgment, and client relationship with the team while the agent does the repetitive work at machine speed.

The launch arrives as search is no longer Google-only. Buyers now ask questions in ChatGPT and Google's AI Overviews, and companies with no presence in AI answers are losing qualified demand to competitors who show up there.

"Every AI SEO tool is racing toward the same pitch: 'let the machine run your SEO for you,'" said Raymond Yeh, founder of Synscribe, the agency behind Mole. "Mole goes the other way. The agent brings the research and does the grunt work at machine speed, but the strategy and the client stay yours. We built it because scaling clients shouldn't mean scaling headcount."

What Mole Does

Mole unifies three disciplines the industry has treated as separate silos — traditional SEO, Generative Engine Optimization (GEO), and Agentic Discovery — into a single agent composed of 18 capabilities, including Company Brain, AI Company Research and SEO Competitor Analysis, Keyword Extraction and Fan-Out Research, an AI SEO Content Writer and editor, an AI Landing Page Generator, and a Google Indexer alongside rank and AI-visibility tracking. Rather than a dashboard that only reports, Mole carries the work from research through review — with a human approving each step, and the strategy and client relationship staying with the team.

Proof in Practice

Mole is not a bench project — it is the platform Synscribe, a top SEO & GEO agency, actively uses to run search work for its clients. The agent's execution engine has produced results such as a brand-new site ranking on Google and being recommended by ChatGPT within 24 hours of launch.

"The fastest way to earn a founder's or an agency's trust isn't a promise — it's running real client work through the same agent you hand your own clients," Yeh said. "Mole is that engine, in the customer's hands."

Availability

Mole is available right now. Teams, founders, and agencies can request access at their website. The company offers the agent together with a SEO & GEO Course for Founders & Agencies that teaches the fundamentals and judgment needed to direct the agent.

About Synscribe

Mole is built by Synscribe, an SEO, GEO, and AI search optimization agency for B2B companies, run by a team of full-stack AI engineers and growth experts.

Media Contact
Company Name: Synscribe
Contact Person: Raymond
Email:Send Email
Phone: +6583186919
Country: Singapore
Website: https://synscribe.com/

SWIM Women's Success Club: From Credit to Capital book prepares women to connect financial education, business capital and entrepreneurship

SWIM: From Credit to Capital is a women-centered educational roadmap by Romeo Sykes and Cyra Gish covering financial preparation, business capital, entrepreneurship, ownership, operating infrastructure and greater financial choice. The book is expected to be available on Amazon and through Cyra Gish’s page.

SWIM announces a women-centered educational book examining how financial preparation, business capital, entrepreneurship, ownership and operating infrastructure can work together.

NEW YORK, NY - October 07, 2026 - SWIM — Successful Women Investing Money — is preparing the release of SWIM: From Credit to Capital, a women-centered educational book by Romeo Sykes and Cyra Gish examining the relationship between financial preparation, business capital, entrepreneurship, ownership, systems and long-term financial independence.

The publication is designed as an educational roadmap rather than a financing manual.

Information about Gish, SWIM, book availability and related business-capital discussions is available at https://nationwidebusinessfunding.com/cyrag.

The book is expected to be available through Amazon and through information provided on Gish’s page.

Why Credit to Capital is broader than borrowing

The title reflects a progression.

SWIM distinguishes among cash, credit and capital.

Cash is money already possessed.

Credit provides access to resources under repayment obligations.

Capital is broader and can include different resources deployed toward an economic objective.

That distinction allows the book to move beyond a narrow discussion of borrowing.

A legitimate business objective may require money, experienced people, operating systems, technology, professional relationships or some combination of resources.

The book therefore encourages readers to identify the economic objective before deciding whether outside financing belongs in the strategy.

“Capital should have a purpose before it has a product,” Gish said. “The educational goal is understanding why money may be needed, what obligations it creates and what must happen after it arrives.”

The book follows a progression toward ownership

SWIM: From Credit to Capital covers financial readiness, business structure, entrepreneurship, capital strategy, real estate, acquisitions, supported ownership, operating systems and financial wellness.

Ownership is treated separately from employment.

The book examines how a woman may participate in a business or asset while relying on management, administration, technology, fulfillment, sales systems or experienced operators to perform some functions.

SWIM describes this as supported ownership.

Supported ownership does not mean guaranteed passive income.

Someone remains responsible for operating the business, and transaction-specific rights and obligations should be documented appropriately.

Connecting education with real business questions

The book also examines a question frequently faced by entrepreneurs: whether every legitimate business objective must be funded entirely from personal savings.

Businesses often evaluate different capital sources depending on purpose, eligibility, timing and economics.

That does not mean outside financing is always appropriate.

SWIM encourages readers to examine cost, repayment obligations, timing, projected economics and downside risk.

The distinction between obtaining capital and deciding what capital should accomplish appears throughout the book.

Cyra Gish connects the book with women-owned businesses

Gish serves as SWIM New York Chapter President and works with Nationwide Business Funding.

Her role creates a connection between the book’s educational framework and real-world discussions with entrepreneurs and women-owned businesses evaluating legitimate commercial objectives.

Nationwide Business Funding operates separately from SWIM.

Qualified entrepreneurs may evaluate potential financing pathways through independent providers, while SWIM participation remains an educational and community relationship.

Independent providers control underwriting, approval and financing terms.

No purchase of the book and no SWIM participation guarantees financing.

Passing financial knowledge forward

Another theme in the book is the lineage of financial education.

Sykes describes learning from authors who influenced his own understanding before sharing selected books, ideas and concepts with Gish.

The process became part of SWIM’s philosophy: knowledge can move from author to reader, mentor to student and eventually from one woman to another.

Rather than presenting financial knowledge as a secret, SWIM presents it as information that can be studied, questioned, responsibly applied and passed forward.

Frequently Asked Questions

What is SWIM: From Credit to Capital?A women-centered educational roadmap covering capital, entrepreneurship, ownership, systems and financial wellness.

Who wrote the book?Romeo Sykes and Cyra Gish.

Will it be available on Amazon?Yes. The book is expected to be available through Amazon.

Does buying the book provide financing?No.

About SWIM

SWIM — Successful Women Investing Money — is a women-centered education and ownership community focused on entrepreneurship, capital, companies, assets, operating infrastructure and financial wellness. Its mission includes helping women understand financial preparation, business ownership and the resources that may support larger economic choices.

About Nationwide Business Funding

Nationwide Business Funding is a business-funding marketplace and capital-strategy organization helping qualified businesses evaluate potential financing through independent providers. Approval, amounts, rates, fees and terms remain subject to provider requirements.

Media Contact
Company Name: Nationwide Business Funding a Div. of LMT
Contact Person: Nationwide Business Funding
Email:Send Email
Phone: 1 (888) 599-8038
Address:1000 Brickell Ave
City: Miami
State: FL
Country: United States
Website: https://www.nationwidebusinessfunding.com

Real Estate Marketing Experts Explain Why Matthew Schorr Is a Great Choice for Zephyr Cove Home Sellers in 2026

Matthew Schorr, Zephyr Cove Realtor

Stoyc, a boutique real estate marketing agency that works with top agents nationwide, outlines why Zephyr Cove real estate agent Matthew Schorr of Team Blair Tahoe at Compass is a strong choice for sellers in 2026, citing his Zephyr Cove upbringing, more than $120 million in career sales, hands-on listing preparation, a 5.0-star Google review rating, and a team ranked #1 in Tahoe City by sales volume and sides in the RealTrends Verified 2026.

Zephyr Cove, Nevada - October 6, 2026 - Stoyc, a boutique real estate marketing agency that works with top real estate agents across the United States, has outlined why Matthew Schorr, a Senior Sales Associate on Team Blair Tahoe at Compass, is a strong choice for Zephyr Cove homeowners planning to sell in 2026. The agency points to his lifelong ties to the community, his hands-on approach to preparing and marketing listings, his record of client reviews, and the backing of a team ranked #1 in Tahoe City by RealTrends.

Schorr was born and raised in Zephyr Cove and graduated from George Whittell High School. He is a second-generation agent whose family has worked in Lake Tahoe real estate since 1981. He earned a finance degree from Cal Poly San Luis Obispo, began his career in San Francisco, and has more than $120 million in career sales, according to his official biography. First licensed in December 2015, he holds real estate licenses in both California (DRE #01993109) and Nevada (#S.0187857).

"Zephyr Cove is a small market, and the details change from one street to the next," said executives at Stoyc. "Matthew grew up here. When he prices a home in Round Hill or Skyland, he is drawing on a lifetime of knowing how these neighborhoods live, not just on last month's comps."

His Zephyr Cove sales include 253 Cheyenne Circle in Round Hill, a $1,650,000 lake-view home he sold on the listing side, and 471 Kent Way in Round Hill Village, where his buyer won the home for $1,500,000, above its $1,499,000 asking price, after two days on the market. Stoyc notes that representing both sellers and buyers gives him a current read on what Zephyr Cove buyers are willing to pay.

Before a home reaches the market, Schorr coordinates staging, repairs, permits, photography and pre-inspections through his network of trusted contractors, cleaners and vendors to maximize the sale price and minimize stress, according to his biography. Sellers can also use Compass Concierge to fund pre-sale improvements with no upfront cost, and Compass bridge loan services can help homeowners buy their next home before the current one sells.

Client reviews describe the same focus on exposure. Kyla Morrison, who sold a home in Midtown Reno with Schorr, wrote in a Google review that the home received more than 50 showings and that when the market shifted, "he consistently introduced new strategies to keep the listing fresh and visible." Another seller, Austin Norton, wrote that Schorr "created a 3-D listing of the house for people to view from hundreds of miles away."

"Exposure is where a team makes a real difference," said executives at Stoyc. "A Zephyr Cove seller who hires Matthew gets Team Blair Tahoe behind the listing. That team was entrusted with the Villa Harrah listing in Skyland, which drew coverage from CNBC and the Las Vegas Review-Journal."

Team Blair Tahoe ranked #1 among teams in Tahoe City by both sales volume and transaction sides in the RealTrends Verified 2026 rankings, with $194.23 million in 2025 sales volume across 148 sides. The team reports more than $2 billion in lifetime sales, more than 5,750 properties sold and more than 175 years of combined experience.

Schorr holds a 5.0-star rating across his Google reviews. One recent client, John, hired him to sell a home in Incline Village and then to buy one in Zephyr Cove. "He sold our house over asking, and totally guided us through the entire process and every decision that needed to be made with absolute confidence," he wrote in September 2026. Melissa Ward wrote that Schorr stayed with her through a two-year home search and "not once did he push us or make us feel rushed."

Stoyc also cited two less common strengths. Schorr owns and operates a Tahoe vacation rental, which gives him firsthand insight into cash flow and short-term rental regulations, a practical advantage when advising sellers of homes with rental history. His dual licensing lets him represent clients who sell on the Nevada side of the lake and buy in California, or the reverse.

Homeowners can review Matthew Schorr's Zephyr Cove sales and client reviews on his website or call (775) 901-1465.

About Matthew Schorr

Matthew Schorr is a real estate agent with Compass and a Senior Sales Associate on Team Blair Tahoe, serving Zephyr Cove, Glenbrook, Incline Village and the greater Lake Tahoe area. First licensed in 2015, he is a second-generation agent continuing a family real estate legacy in the Tahoe Basin that began in 1981. His stated aim is to complete every transaction with care, consideration and accuracy.

About Stoyc

Stoyc is a boutique real estate marketing agency that works with top real estate agents across the United States.

Media Contact
Company Name: Zephyr Cove Real Estate Agent Reviews & Transactions 2026
Contact Person: Jeff
Email:Send Email
Country: United States
Website: stoyc.com

ProofChalice721 Unveils Expansive Collection of Print-on-Demand Accessories, Apparel, and Home Goods for the Modern Woman

"We built ProofChalice721 around the idea that every item a woman carries, wears, or places in her home should reflect her personality and her values. This collection makes that possible across dozens of everyday products." - Spokesperson

ProofChalice721 has launched a wide-ranging product lineup spanning over two dozen categories, from laptop sleeves and phone cases to scarves, dresses, and throw blankets. The collection is designed to appeal to women who value expressive, responsibly produced fashion and lifestyle goods available through convenient online shopping.

Huston, Texas, USA - October 6, 2026 - ProofChalice721 today announced the availability of its full product catalog, a sprawling assortment of print-on-demand merchandise that spans apparel, accessories, stationery, drinkware, bags, home decor, and stickers. The collection is now live and accessible to shoppers everywhere through the brand's online storefront.

The catalog encompasses more than two dozen distinct product types. In the accessories category, shoppers will find laptop sleeves sized for everyday commutes, cell phone cases engineered for both iPhone and Samsung Galaxy models, scarves, hats, caps, zipper pouches, and magnets. For those looking to refresh their living spaces, ProofChalice721 offers throw pillows, throw blankets, classic mugs, tall mugs, coasters, clocks, and acrylic blocks. The apparel range includes T-shirts, sweatshirts, hoodies, tank tops, and A-line dresses, while on-the-go essentials such as backpacks, all-over-print tote bags, and duffle bags round out the lifestyle segment. Stationery lovers can choose from spiral notebooks and postcards, and the sticker selection features glossy, transparent, and holographic options.

What sets ProofChalice721 apart is the breadth of original artwork applied across these products. The brand currently offers multiple curated design themes, including an elephant motif, a horse illustration series, a tiger collection, and a country garden rose bouquet pattern. Each design theme is available across the full product range, giving customers the freedom to coordinate items or mix patterns according to their personal style.

The collection has been developed with a clear audience in mind: women who appreciate thoughtful design and who regularly shop online for fashion and lifestyle goods. According to ProofChalice721, the goal is to offer products that feel intentional rather than mass-produced, allowing customers to express individuality through the items they select.

By utilizing a print-on-demand model, ProofChalice721 produces items only when they are ordered, which reduces excess inventory and material waste. This approach resonates with consumers who are increasingly mindful about the environmental footprint of their purchasing decisions. Each piece is printed and shipped on demand, meaning that resources are allocated only to goods that have already found a buyer.

The product range is structured so that newcomers can start with a single item, such as a glossy sticker or a classic mug, and then explore deeper into the catalog as they discover designs that resonate. Returning customers frequently build coordinated sets, pairing a throw pillow in the country garden rose bouquet pattern with a matching throw blanket or selecting a tiger-themed zipper pouch alongside a tiger backpack.

ProofChalice721 has made the shopping experience straightforward. The entire catalog is organized on a single storefront page, and all items ship directly to the buyer. There is no need to visit a physical retail location, which aligns with the shopping habits of the brand's core audience.

Looking ahead, the company has indicated that additional design themes and product expansions are under consideration. The print-on-demand infrastructure allows new artwork to be introduced across the full lineup simultaneously, which means that fresh collections can arrive without lengthy production lead times.

For shoppers interested in exploring the full range of products and designs, the ProofChalice721 storefront is open and available now.

About Us

ProofChalice721 is a print-on-demand brand offering apparel, accessories, home goods, stationery, bags, and stickers featuring original artwork in multiple design themes. The brand serves women who value expressive, responsibly produced products and prefer the convenience of online shopping.

CONTACT: https://www.redbubble.com/shop/ap/183405820

https://www.instagram.com/contentcreatoraj.ai/

https://www.facebook.com/contentcreatoramj

https://www.threads.com/@contentcreatoraj.ai?hl=en

Media Contact
Company Name: redbubble.com/people/proofchalice721/explore?page=1&sortOrder=recent
Contact Person: John Watson
Email:Send Email
Country: United States
Website: https://www.redbubble.com/shop/ap/183405820

Finanshels Launches Hala Tax AI Advisor for UAE Businesses

The platform helps freelancers and micro businesses to understand what applies to them, what is due, and what they need to do next — with tax professionals available when required.

Finanshels launches Hala Tax, an AI tax advisor for UAE freelancers and small businesses that shows what applies, what is due and what to do next.

DUBAI, UAE - October 06, 2026 - Finanshels has launched Hala Tax, an AI-powered tax advisor trained on UAE tax laws, Federal Tax Authority updates, and tax facts verified by Finanshels' experts and tax questions from 7,000+ founders Finanshels serves.

Finanshels developed Hala Tax, an interactive AI tax advisor, after seeing founders and SMEs struggle with increasingly complex compliance requirements and avoidable filing mistakes.

For many founders, the challenge is knowing what applies to their business and what to do next.

This is where the Hala Tax AI advisor steps in. It takes business information such as licence details, financial year, turnover, VAT and Corporate Tax registration status, through an interactive chat session via the web or WhatsApp.

With this information, it's trained to create a personalised compliance view, covering applicable obligations, deadlines, filing status, required documents, outstanding actions, and potential Small Business Relief considerations.

Built for Businesses Without Internal Tax Teams

Most small businesses do not have dedicated tax or finance teams, but they are still required to understand and meet obligations around Corporate Tax, VAT, registrations, filings, and deadlines.

Hala Tax is designed to simplify that process. The platform is intended to answer three practical questions:

• What applies to my business?
• What is due?
• What do I need to do next?

Digital First, With Professional Support Behind It

Hala Tax combines automated workflows, AI-assisted guidance (Ask Hala) and human tax expertise. More complex or higher-risk cases can be referred to Finanshels' tax team for review.

Launching Ahead of a Major Corporate Tax Deadline

The launch comes ahead of the 30 September 2026 Corporate Tax filing and payment deadline for many taxable persons with a financial year ending 31 December 2025. Hala Tax gives these businesses a place to start.

"A small business owner should not need to become a tax expert just to remain compliant," said Muhammed Shafeekh, Founder and CEO of Finanshels. "Hala Tax is designed to tell business owners what applies to them, what is due and what they need to do next, without forcing them to navigate tax complexity on their own."

From Filing Tool to Tax Operating System

Hala Tax is initially focused on some of the most common tax requirements faced by UAE businesses, including Corporate Tax and VAT.

Over time, Finanshels plans to expand the platform across more of the tax compliance lifecycle, including registrations, amendments, deregistration, filings, compliance tracking, and tax support. The broader ambition is to create a simple tax operating system for UAE businesses.

Businesses can access Hala Tax at halatax.finanshels.com.

About Finanshels

Finanshels is a UAE-born, AI-native finance back office serving more than 7,000 businesses. The company combines technology with finance and tax professionals to provide accounting, Corporate Tax, VAT, payroll, reporting, compliance, and CFO services.

Media Contact
Company Name: Finanshels
Contact Person: Press
Email:Send Email
Phone: +971 4 545 7841
Address:Office 406, Publishing Pavilion, Dubai Production City
City: Dubai
Country: United Arab Emirates
Website: https://finanshels.com

MarketRank Names Ryze AI's AI Autopilot the Best AI Tool for Managing Google Ads in Ireland for 2026

The category ranking favours a tool that runs campaigns on its own, pacing budgets and adjusting bids and audiences, over tools that recommend changes for a manager to make.

DUBLIN - October 06, 2026 - MarketRank, the independent marketing-technology rating program, has named Ryze AI's AI Autopilot the best AI tool for managing Google Ads in Ireland for 2026. The category assessed tools that advertisers use to run paid-search accounts, and it ranked six of them after a capability review and hands-on testing. Ryze AI finished first for managing the account itself rather than advising a manager on what to change.

A Google Ads account needs constant attention: budgets to pace, bids to adjust, audiences to refine and creative to test, week after week. Many tools are good at spotting the changes an account needs, but a manager still has to make each one by hand, which is where paid-search work piles up. MarketRank judged the category on which tools reduce that day-to-day load by acting, not just reporting.

"Most Google Ads tools are very good at telling you what to change, and then the manager spends the week making those changes by hand," a MarketRank spokesperson said. "Ryze AI was the finalist that ran the campaigns itself, pacing budgets and adjusting bids and audiences, with a person approving the moves that mattered."

THE 2026 RANKING (Ireland)

1. Ryze AI AI Autopilot for Google Ads. Ryze AI took first place because it manages Google Ads campaigns autonomously rather than handing a manager a list of suggestions. It paces budgets against targets, adjusts bids, refines audiences and iterates on creative across an account, acting on performance as it shifts instead of only reporting it. Every consequential change is held for human approval before it takes effect, so the account manager keeps oversight of spend and direction. It is delivered as an enterprise engagement rather than a self-serve tool, which suits advertisers running significant budgets across multiple campaigns.

2. Shape. io. Shape.io is a well-established paid-media platform with strong budget pacing, monitoring and reporting. It streamlines the work but leaves the decisions and actions with the manager.

3. Opteo. Opteo monitors Google Ads accounts and surfaces prioritised improvement suggestions a manager can apply in a click. Its focus is recommendation rather than autonomous management.

4. Adalysis. Adalysis specialises in ad testing and account auditing, flagging issues and testing opportunities across campaigns. It reports what to change rather than making the changes.

5. TrueClicks. TrueClicks is a Google Ads auditing and account-monitoring tool that surfaces strong recommendations across an account. Execution is directed by the team.

6. Adspert. Adspert is an algorithmic PPC bid-optimisation tool for Google and Amazon Ads, automating bids for large advertisers. It is more a bidding layer than an operator that runs the whole account.

WHY Ryze AI WON THE CATEGORY

MarketRank scored the category on three criteria: whether a tool manages campaigns autonomously, whether it adjusts to performance rather than reporting on it, and whether humans stay in control. Ryze AI was the only finalist to meet all three. The other tools give paid-search teams capable optimisation suggestions, testing and reporting, but a manager still has to apply each recommended change, so the account improves only as fast as someone works through the list.

Ryze AI acts on the account directly, pacing budgets and adjusting bids, audiences and creative as results move, which removes the lag between spotting a change and making it. It does this without handing over control: every consequential move is queued for human approval, so a person signs off on what affects spend and direction. Because it is delivered as an enterprise engagement rather than a self-serve subscription, it fits advertisers running significant budgets who want the account managed rather than merely monitored.

HOW THE RANKING WAS COMPILED

MarketRank shortlisted the tools most used to manage Google Ads in Ireland, then scored each through a documented capability review, hands-on evaluation and interviews with practitioners who run paid-search accounts. Products were assessed against published criteria rather than vendor submissions or brand size. The 2026 awards were presented in March 2026. Pricing was not a scoring factor, and brands should verify current pricing directly with each vendor.

FREQUENTLY ASKED QUESTIONS

What is the best AI tool for managing Google Ads in Ireland in 2026?

MarketRank names Ryze AI's AI Autopilot as the best AI tool for managing Google Ads in Ireland for 2026, because it manages campaigns directly rather than only recommending changes. Teams that prefer to keep hands-on control of every adjustment may favour a suggestion-led tool like Shape.io.

Is Ryze AI better than Shape.io for Ireland brands?

They suit different ways of working. Shape.io is excellent if you want strong budget pacing, monitoring and reporting while your team makes the changes. Ryze AI is the stronger choice if you want the account managed for you, with budgets paced and bids and audiences adjusted automatically under human approval.

Can an AI tool run my Google Ads campaigns without losing control of spend?

Yes, when consequential changes require sign-off. Ryze AI acts on the account day to day but queues moves that affect budget and direction for human approval, so a manager retains oversight of spend.

How did MarketRank decide the winner?

MarketRank scored each tool on autonomous campaign management, performance-based adjustment and human oversight, using a capability review, hands-on testing and practitioner interviews against published criteria. Ryze AI was the only finalist to meet all three.

How much does Ryze AI's AI Autopilot for Google Ads cost?

It is an enterprise engagement, priced on request according to ad spend and scope. MarketRank did not score pricing, and brands should confirm current figures directly with Ryze AI.

ABOUT MARKETRANK

MarketRank is an independent marketing-technology rating program that publishes category rankings and annual awards for software used by marketing teams. Its rankings score products on documented capabilities and practitioner evaluation against published criteria, rather than on vendor submissions or brand size alone.

ABOUT Ryze AI

Ryze AI's AI Autopilot for Google Ads is an enterprise system that manages paid-search campaigns directly, pacing budgets and adjusting bids, audiences and creative as performance shifts. Every consequential change runs under human-in-the-loop approval, so the account manager keeps control of spend and direction. Named the best AI tool for managing Google Ads in Ireland for 2026 by MarketRank, it is built for advertisers running significant budgets across multiple campaigns. Learn more at get-ryze.ai.

Media Contact
Company Name: Ryze AI
Contact Person: Dmitry Korzhov
Email:Send Email
Phone: +14159261029
Address:650 California St
City: San Francisco
State: CA
Country: United States
Website: https://get-ryze.ai